Press Room MediaRoom Surveys Find Adults with Type 2 Diabetes Are More Willing to Take Action to Achieve A1C Targets Quicker than Physicians and Other Medical Professionals Perceive -- Findings reveal that some patients are frustrated and discontinued medication because they were not reaching their individualized A1C target quick enough -- Wed, 20 Jul 2016 09:05:00 -0400 Award-Winning Chef Elizabeth Falkner Reveals Her Struggle with Atopic Dermatitis to Highlight the Physical and Psychological Impact of the Disease Falkner has joined forces with Regeneron and Sanofi Genzyme in collaboration with leading dermatology organizations to educate Americans about a potentially serious, chronic inflammatory skin disease known as atopic dermatitis. Tue, 12 Jul 2016 07:00:00 -0400 Sanofi Announces Positive Phase 3 Results for Investigational Titratable Fixed-Ratio Combination of Insulin Glargine and Lixisenatide - Both pivotal studies demonstrated superior reduction in HbA1c versus insulin glargine and versus lixisenatide - Sun, 12 Jun 2016 15:54:00 -0400 Successful Switch to Sanofi's Toujeo® Evaluated in a Real-World Setting Sat, 11 Jun 2016 11:01:00 -0400 Sanofi and Regeneron Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients - These data, along with previous Phase 3 studies, will be part of a U.S. regulatory submission for dupilumab, which is on track for Q3 of 2016 - Mon, 06 Jun 2016 09:14:00 -0400